Stocky turns companies like TAISHO PHARMACEUTICAL HLDG CO L into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. TAIPY scores 31/100 overall, with weak Growth (37.5) and Value (25) signals indicating limited earnings expansion and unattractive valuation relative to fundamentals. Leadership Alignment at 52/100 suggests misaligned incentives between management and shareholders, compounded by a Vulnerable profile that points to structural competitive or operational headwinds without offsetting moat protection.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for TAISHO PHARMACEUTICAL HLDG CO L:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 31/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates TAISHO PHARMACEUTICAL HLDG CO L (TAIPY) at 31/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. TAIPY scores 31/100 overall, with weak Growth (37.5) and Value (25) signals indicating limited earnings expansion and unattractive valuation relative to fundamentals. Leadership Alignment at 52/100 suggests misaligned incentives betw
TAIPY's current Stocky Verdict is 31/100, placing it in the "Avoid" band. This composite combines a 38/100 Compounder score, 52/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for TAISHO PHARMACEUTICAL HLDG CO L yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
TAISHO PHARMACEUTICAL HLDG CO L scores 52/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
TAISHO PHARMACEUTICAL HLDG CO L's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to TAISHO PHARMACEUTICAL HLDG CO L.
Sign up free and unlock the full analysis on TAIPY — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for TAIPY in the app.
